Patents Examined by Jeanette Lieb
  • Patent number: 9999689
    Abstract: The present disclosure provides compositions and methods based on peptide-detectable agent conjugates that are useful for imaging beta cell mass.
    Type: Grant
    Filed: March 21, 2016
    Date of Patent: June 19, 2018
    Assignee: The General Hospital Corporation
    Inventors: Ralph Weissleder, Thomas Reiner, Edmund J. Keliher
  • Patent number: 9969787
    Abstract: GLP-2 analogs are disclosed which comprise one of more substitutions as compared to h[Gly2]GLP-2 and which may have the property of an altered GLP-1 activity, and their medical use. The analogs are particularly useful for the prophylaxis treatment or ameliorating of the gastro-intestinal associated side effects of diabetes.
    Type: Grant
    Filed: August 16, 2016
    Date of Patent: May 15, 2018
    Assignee: Zealand Pharma A/S
    Inventors: Rasmus Just, Kirsten Lindegaard Bovbjerg, Ditte Riber, Wayne Shaun Russell
  • Patent number: 9956269
    Abstract: The present disclosure relates to a method for increasing the stability of a Factor VIII molecule after purification, lyophilization and reconstitution, comprising preventing proteolytic cleavage of the Factor VIII molecule into a first fragment comprising essentially the A1 domain and the A2 domain and a second fragment comprising essentially the A3 domain, the C1 domain and the C2 domain throughout manufacturing the Factor VIII molecule. The disclosure further pertains to a method for improving the bioavailability of Factor VIII after intravenous and non-intravenous injection.
    Type: Grant
    Filed: May 17, 2016
    Date of Patent: May 1, 2018
    Assignee: CSL Limited
    Inventors: Carsten Horn, Sabine Zollner, Hubert Metzner, Stefan Schulte
  • Patent number: 9950034
    Abstract: The present disclosure relates to methods of treating, ameliorating or preventing a disorder comprising administering a therapeutically effective amount of a composition to a subject in need thereof, which composition contains a lipocalin mutein or a fragment or a variant thereof capable of increasing the bioavailability of iron in the subject.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: April 24, 2018
    Assignee: PIERIS PHARMACEUTICALS GMBH
    Inventors: Andreas Hohlbaum, Hendrik Gille, Stefan Trentmann, Laurent Audoly, Andrea Allersdorfer
  • Patent number: 9951116
    Abstract: The present invention provides peptide analogs of ?-MSH and ?-MSH, comprising the amino acid sequence of human ?-MSH or ?-MSH, or variants thereof, and having a branched amino acid probe in the N-terminal part of the peptide.
    Type: Grant
    Filed: October 10, 2016
    Date of Patent: April 24, 2018
    Assignee: TXP Pharma GmbH
    Inventor: Thomas Boesen
  • Patent number: 9950013
    Abstract: The invention relates to a nutritional composition comprising (a) at least 18 en % of proteinaceous matter, said proteinaceous matter comprising whey; (b) at least 12 wt % of leucine, based on total proteinaceous matter; and (c) a lipid fraction comprising at least a ?-3 polyunsaturated fatty acid selected from the group of eicosapentaenoic acid, docosahexaenoic acid, eicosatetraenoic acid and docosapentaenoic acid for improving the muscle function in a mammal, for improving daily activity, for improving physical performance, for providing a better prognosis in terms of extended life-expectancy, for improving compliance to an anti-cancer therapy or for improving a quality of life.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: April 24, 2018
    Assignee: N. V. Nutricia
    Inventors: Klaske Van Norren, Adrianus Lambertus Bertholdus Van Helvoort, Joyce Faber, Robert Johan Joseph Hageman, Arjan Paul Vos
  • Patent number: 9949949
    Abstract: The present invention provides novel conformationally-defined macrocyclic compounds that can function as selective modulators of the ghrelin receptor (growth hormone sceretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, bone disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.
    Type: Grant
    Filed: June 9, 2016
    Date of Patent: April 24, 2018
    Assignee: Ocera Therapeutics, Inc.
    Inventors: Hamid Hoveyda, Graeme Fraser, Kamel Benakli, Eric Marsault, Mark L. Peterson
  • Patent number: 9944681
    Abstract: Nutritive proteins are provided. In some embodiments the nutritive proteins comprise a first polypeptide sequence comprising a fragment of a naturally-occurring nutritive protein. In some embodiments the fragment comprises at least one of a) an enhanced ratio of branch chain amino acid residues to total amino acid residues present in the nutritive protein; b) an enhanced ratio of leucine residues to total amino acid residues present in the nutritive protein; and c) an enhanced ratio of essential amino acid residues to total amino acid residues present in the nutritive protein.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: April 17, 2018
    Assignee: Axcella Health Inc.
    Inventors: David Arthur Berry, Brett Adam Boghigian, Nathaniel W. Silver, Geoffrey von Maltzahn, Rajeev Chillakuru, Michael Hamill, John F. Kramarczyk
  • Patent number: 9938323
    Abstract: The invention disclosed herein relates to cytotoxic cyclic peptides of Formula (I), methods of inhibiting RNA polymerase with such cyclic peptides, immunoconjugates comprising such cyclic peptides (i.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: April 10, 2018
    Assignee: Novartis AG
    Inventors: Jan Grunewald, Yunho Jin, Weijia Ou, Tetsuo Uno
  • Patent number: 9937222
    Abstract: The present invention provides polypeptide modulators of complement activity, including cyclic polypeptide modulators. Also provided are methods of utilizing such modulators as therapeutics.
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: April 10, 2018
    Assignee: Ra Pharmaceuticals, Inc.
    Inventors: Michelle Denise Hoarty, Ketki Ashok Dhamnaskar, Daniel Elbaum, Kristopher Josephson, Kelley Cronin Larson, Zhong Ma, Nathan Ezekiel Nims, Alonso Ricardo, Kathleen Seyb, Guo-Qing Tang, Douglas A. Treco, Zhaolin Wang, Ping Ye, Hong Zheng, Sarah Jacqueline Perlmutter
  • Patent number: 9931031
    Abstract: Provided herein are methods of diagnosing meibomian gland dysfunction (MGD), determining the severity of meibomian gland dysfunction in a subject, evaluating efficacy of treatment of MGD in a subject, selecting a subject for treatment of MGD, and selecting a subject for participation in a clinical study.
    Type: Grant
    Filed: February 21, 2013
    Date of Patent: April 3, 2018
    Assignee: Massachusetts Eye & Ear Infirmary
    Inventors: Pedram Hamrah, Yureeda Qazi
  • Patent number: 9925237
    Abstract: The present invention provides polypeptide-polymer conjugates. A subject polypeptide-polymer conjugate is useful in a variety of applications, which are also provided.
    Type: Grant
    Filed: July 19, 2016
    Date of Patent: March 27, 2018
    Assignee: The Regents of the University of California
    Inventors: Kevin Edward Healy, Samuel T. Wall, Krishanu Saha, David V. Schaffer
  • Patent number: 9925271
    Abstract: The present invention relates to the preparation and use of therapeutic compounds for the treatment of diseases at specific subcellular target areas such as specific cellular organelles. In particular, the therapeutic compounds of the invention are specific for modifying enzyme activity within targeted organelles or structures of cells and tissues. Subcellular organelles and structures that may be specifically targeted by compounds of the present invention include lysosomes, autophagasomes, the endoplasmic reticulum, the Golgi complex, peroxisomes, the nucleus, membranes and the mitochondria.
    Type: Grant
    Filed: April 3, 2017
    Date of Patent: March 27, 2018
    Assignee: Marker Gene Technologies, Inc
    Inventors: John Joseph Naleway, Fiona Karen Harlan, Jason Scott Lusk
  • Patent number: 9925117
    Abstract: A pre-filled syringe storing an anesthetic is disclosed. The pre-filled syringe includes a container configured to store a liquid anesthetic solution. The liquid anesthetic solution includes an anesthetic, water, and a solvent. The container is made of a plastic that is inert to the anesthetic. The pre-filled syringe also includes a plunger made of siliconized bromobutyl rubber that is inert to the anesthetic and a rubber stopper made of siliconized bromobutyl rubber that is inert to the anesthetic. The plunger and the rubber stopper seal the container configured to store the liquid anesthetic solution.
    Type: Grant
    Filed: May 16, 2013
    Date of Patent: March 27, 2018
    Assignee: Fresenius Kabi USA, LLC
    Inventors: Neil P. Desai, Andrew Yang, Sherry Xiaopei Ci
  • Patent number: 9920095
    Abstract: The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorder, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition including Crohn's disease and ulcerative colitis, and cancer.
    Type: Grant
    Filed: August 20, 2015
    Date of Patent: March 20, 2018
    Assignee: SYNERGY PHARMACEUTICALS, INC.
    Inventors: Kunwar Shailubhai, Gary S. Jacob
  • Patent number: 9919054
    Abstract: The invention relates to compositions comprising (i) biocompatible hydrogel and (ii) one or more therapeutic agents contained within said hydrogel; wherein the hydrogel is cross-linked utilizing a cross-linker comprising a peptide sequence that is capable of being degraded by an enzyme; the therapeutic agent being effective as a treatment of a condition related to the presence of the enzyme.
    Type: Grant
    Filed: May 22, 2017
    Date of Patent: March 20, 2018
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Jason Alan Burdick, Robert C. Gorman, Joseph H. Gorman, III, Brendan Patrick Purcell
  • Patent number: 9920105
    Abstract: A fusion polypeptide, including a first polypeptide fragment including 5 to 30 amino acids, the first polypetide fragment is fused between a first amino acid and a fifth amino acid of a fourth loop of a human-derived ferritin monomer.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: March 20, 2018
    Assignee: Kyungpook National University Industry-Academic Cooperation Foundation
    Inventors: Eunsung Jun, Jaeog Jeon, Soyoun Kim, In-Seop So, In-San Kim, Sun-Ji Kim
  • Patent number: 9913916
    Abstract: Asymmetric bifunctional silyl (ABS) monomers comprising covalently linked pharmaceutical, chemical and biological agents are described. These agents can also be covalently bound via the silyl group to delivery vehicles for delivering the agents to desired targets or areas. Also described are delivery vehicles which contain ABS monomers comprising covalently linked agents and to vehicles that are covalently linked to the ABS monomers. The silyl modifications described herein can modify properties of the agents and vehicles, thereby providing desired solubility, stability, hydrophobicity and targeting.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: March 13, 2018
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Joseph M. DeSimone, Mathew Finniss, Mary Napier, Ashish Pandya, Matthew Parrott
  • Patent number: 9914754
    Abstract: The present invention features a compound having the formula A-X-B, where A is peptide vector capable of enhancing transport of the compound across the blood-brain barrier or into particular cell types, X is a linker, and B is a peptide therapeutic selected from the group consisting of neurotensin, a neurotensin analog, or a neurotensin receptor agonist. The compounds of the invention can be used to treat any disease in which increased neurotensin activity is useful and can be used to induce hypothermia or analgesia.
    Type: Grant
    Filed: December 7, 2009
    Date of Patent: March 13, 2018
    Assignee: Angiochem Inc.
    Inventors: Jean-Paul Castaigne, Michel Demeule, Christian Che, Carine Thiot, Catherine Gagnon
  • Patent number: 9907860
    Abstract: This invention relates to a conjugated molecule comprising a peptide derived from the CD4 receptor coupled to an organic molecule by means of a linker as well as a process for its preparation. Said organic molecule comprises a 5 to 21 amino acid anionic polypeptide. Such a conjugated molecule can be used in antiviral treatment, namely in the treatment of AIDS.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: March 6, 2018
    Assignees: INSTITUT PASTEUR, COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, UNIVERSITE PARIS-SUD, UNIVERSITE GRENOBLE ALPES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Francoise Baleux, Hugues Lortat-Jacob, David Bonnaffe, Yves-Marie Coic